<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3035636/" ref="ordinalpos=522&amp;ncbi_uid=3763739&amp;link_uid=PMC3035636" image-link="/pmc/articles/PMC3035636/figure/F2/" class="imagepopup">Figure 2. Canonical Wnt <span class="highlight" style="background-color:">signaling</span> and dysregulation in cancer.  From: Drug Discovery Approaches to Target Wnt <span class="highlight" style="background-color:">Signaling</span> in Cancer Stem Cells. </a></div><br /><div class="p4l_captionBody">The Wnt signaling pathway is comprised of extracellular, cytoplasmic and nuclear signaling events that are amenable to therapeutic intervention. Dysregulation at these stages are common in numerous cancers, captured in the white boxes. Upon entering the nucleus and interacting with TCF/LEF and various co-activators, Î²-catenin drives transcription of programs critical for CSCs, tumor cells and EMT.</div></div>